Contact Dermatitis: Patch Testing, Allergens and Prevention
Irritant vs allergic contact dermatitis, what patch tests can and cannot show, and the evidence on barrier creams, steroids and common allergens.
Independent, evidence-based research on eczema and atopic dermatitis — supplement and management claims graded against primary studies, no industry spin.
Irritant vs allergic contact dermatitis, what patch tests can and cannot show, and the evidence on barrier creams, steroids and common allergens.
Ketoconazole shampoo has the best independent support for seborrhoeic dermatitis, but the evidence is modest, and many trials were company-funded.
Permethrin and oral ivermectin clear scabies about equally by week two, but permethrin resistance is disputed and UK supply has been unreliable.
Biologics and topical treatment are the established route for plaque psoriasis. Fish oil and vitamin D show no clear benefit, and curcumin evidence is weak.
Stress shedding (telogen effluvium) usually regrows on its own. Independent evidence on causes to rule out, minoxidil, biotin risks and who funds hair-supplement trials.
Small varied astaxanthin trials report moisture and elasticity signals, with uncertain practical benefit. They do not establish sunscreen replacement or human lifespan extension; dose rules, safety and financial limits are preparation-specific.
Small commercially supported glutathione trials show mixed pigmentation and antioxidant-marker findings. Limited wrinkle measurements do not establish general anti-aging, detoxification or lasting whitening. Injection alerts concern specific cosmetic-use and compounding risks; long-term and medicine-combination safety remain uncertain.
Key takeaways No supplement cures eczema — vitamin D and omega-3 studies have mixed or preliminary signals, while probiotics are not supported as routine treatment; any supplement considered is an adjunct to moisturizers and prescribed anti-inflammatory treatment. Vitamin D evidence conflicts: a 2024 meta-analysis of 11 RCTs (686 participants) found a modest severity reduction (SMD … Read more
Key takeaways A 2017 Cochrane review included 77 moisturizer studies with 6,603 participants. Its flare analysis used six studies and 607 participants: moisturizer groups had lower flare risk than vehicle, placebo or no moisturizer (RR 0.33, 95% CI 0.17–0.62; moderate-certainty evidence). This concerns established atopic eczema, not prevention of a first diagnosis; 46 trials reported … Read more
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.